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Abstract 
Background: In Uganda, the emerging Uganda genotype of Mycobacterium tuberculosis is the most common cause 
of pulmonary tuberculosis (PTB), and accounts for up to 70 % of isolates. Extrapulmonary TB (EPTB) is less studied in 
Uganda.
Methods: Molecular characterization using deletion analysis and spoligotyping was performed on 121 M. tubercu-
losis isolates from lymph node fine needle biopsy aspirates of Ugandan patients with tuberculous lymphadenitis. The 
evolutionary relationships and worldwide distribution of the spoligotypes were analyzed.
Results: Mycobacterium tuberculosis was the only cause of EPTB in this study. The T2 sublineage was the most 
predominant lineage and the Uganda genotype was the dominant genotype. There were 54 spoligotype patterns 
among the 121 study isolates. The dominant spoligotypes were shared international types (SIT) SIT420, SIT53, SIT 135, 
SIT 128 and SIT590 in descending order. All but SIT420 were previously reported in pulmonary TB in this setting. The 
phylogenetic analysis showed a long descendant branch of spoligotypes belonging to the T2-Uganda sublineage 
containing specifically SITs 135, 128 and 420.
Conclusion: In most cases, the spoligotypes were similar to those causing PTB, but the Uganda genotype was found 
to be less common in EPTB than previously reported for PTB in Uganda. The phylogenetic analysis and the study of 
the worldwide distribution of clustered spoligotypes indicate an ongoing evolution of the Uganda genotype, with 
the country of Uganda at the center of this evolution.
© 2015 Wamala et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Tuberculosis (TB) is a leading infectious cause of mor-
bidity and mortality, responsible for an estimated annual 
8.2 million new cases and 1.4 million deaths globally 
[1]. About one quarter of TB cases occur in Africa [1]. 
Uganda with an incidence of 299 and a mortality of 84 
cases per 100,000 per year, is ranked 16th among the 22 
countries with the heaviest burden of TB [2]. Although 
pulmonary TB (PTB) is the major type of TB, extrapul-
monary TB (EPTB) [3] is associated with a high morbid-
ity and mortality [4] and requires special attention [5]. TB 
lymphadenitis is the commonest extrapulmonary mani-
festation of EPTB [6]. Of 4072 patients seen in 2012 at 
the Mulago National Referral Hospital (MNRH) Tuber-
culosis Clinic, the largest TB treatment center in Uganda, 
902 (22  %) had EPTB [7]. EPTB also offers diagnostic 
challenges because of the paucibacillary nature of EPTB 
specimens, necessitating culture and molecular analysis 
for efficient diagnosis.
Mycobacterium tuberculosis has evolved into geneti-
cally diverse lineages and sublineages [8], and the genetic 
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variety has ramifications including significant variation in 
virulence [9]. The development of molecular techniques 
allows for the identification and tracking of individual 
strains of M. tuberculosis [10]. In Uganda, the emerg-
ing Uganda genotype of M. tuberculosis is the prevalent 
cause of PTB, and accounts for up to 70 % of isolates [11]. 
In a recent study of tuberculous lymphadenitis patients, 
we found that the Uganda genotype was also a major 
aetiological agent in EPTB [12].
Our objective was to analyze the genetic diversity of 
the clinical isolates from this study [12], and to com-
pare them with the genotypic patterns of PTB isolates 
reported previously in this setting [11] in order to under-
stand the epidemiological and phenotypic characteristics 
of M. tuberculosis strains causing EPTB.
Methods
Ethical considerations
The study was reviewed and approved by the Institutional 
Review Board of Makerere University School of Medicine 
and the Uganda National Council for Science and Tech-
nology. Written informed consent to obtain samples as 
well as to use isolates from the samples for studies was 
obtained from all enrolled study participants or their 
legal guardians.
Study design and population
Isolates of M. tuberculosis complex were studied from 
patients presenting with superficial persistent lymph 
node enlargement, at the Fine Needle Aspiration Clinic, 
at MNRH, Kampala. Altogether 121 lymph nodes iso-
lates, each representing one patient, collected between 
February 2010 and July 2012 were included. EPTB 
patients were included with or without pulmonary clini-
cal features.
The patients’ clinical, radiological and pathological 
features were described previously [12]. Of the patients 
in the study, 58 (47.9 %) were males with a mean age of 
30.3 years and 62 (52.1 %) were females with a mean age 
of 27.1 years. The gender of one patient was not recorded. 
Seventy-five (65.8  %) were HIV seropositive while 39 
(34.2  %) were HIV negative. Seven (5.9  %) did not con-
sent to HIV testing.
To confirm that all the isolates were mycobacteria, 
polymerase chain reaction (PCR) was performed using 
16s reverse and 16s forward primers (Integrated DNA 
Technologies) to target the 16s rRNA region with a con-
served sequence that is typical for genus Mycobacterium 
[13–15].
Furthermore, using an in-house PCR, we confirmed 
presence of M. tuberculosis complex members by ampli-
fication of the insertion sequence IS6110 with aid of 
reverse and forward IS6110 primers (Integrated DNA 
Technologies). Presence of bands on the gel of a size of 
approximately 500 bp signified positive results [16].
Region of difference analyses
The lineages and sublineages of M. tuberculosis isolates 
were determined by PCR based genomic deletion analy-
sis for the presence or absence of specific regions of dif-
ference (RD), RD1, RD4, RD9, RD14, RD724, RD750 and 
RD105 using standard protocol [13]. RD 9 ruled out other 
species and confirmed that the cases were M. tuberculo-
sis, RD4 and RD 14 ruled out M. bovis, the RD724 dele-
tion is characteristic of Uganda genotype while RD105 
deletion is specific for Beijing strains. The analyses were 
performed using a previously described method [13].
Spoligotyping
All M. tuberculosis complex strains were assayed by spo-
ligotyping using standard protocols [10] and following 
manufacturer’s instructions (reagents from Ocimum Bio-
solution, custom MasterMix from ABgene). The presence 
of spacers was visualized on film as black squares after 
incubation with streptavidin-peroxidase and ECL chemi-
luminescence detection reagents (RPN 2105 Amersham, 
GE Healthcare Bio-sciences). The spacer hybridization 
patterns were translated into binary and octal format as 
previously described [17]. The 43-digit binary code was 
converted to 15-digit octal code (base 8, having the digits 
0–7) [17].
The binary codes of the isolates were entered into the 
SITVIT2 database of the Pasteur Institute of Guadeloupe 
and assigned specific shared international spoligotype 
signatures (SIT) according to the SITVIT2 data base [18].
Identification of Uganda genotype
The Uganda genotype is a sublineage of the T2 lineage 
and was identified by the lack of RD724 on RD analysis 
[19], and by the lack of spacers 33–36 and spacer 40 and/
or 43 by spoligotyping [20, 21].
Phylogenetic analysis
The evolutionary relationships between the spoligo-
types of the 121 isolates was studied by (a) a Minimum 
Spanning Tree (MST) constructed on all isolates, (b) a 
spoligoforest tree drawn as a hierarchical layout and (c) 
a spoligoforest tree drawn using the Fruchterman–Rein-
gold algorithm. Both spoligoforests were drawn using the 
spolTools software (http://www.emi.unsw.edu.au/spol-
tools/) [22, 23].
The worldwide distribution of clustered spoligotypes 
found in this study was further investigated using the 
SITVIT2 database, and was recorded for regions and 
countries representing ≥3  % of a given SIT as com-
pared to their total number in the SITVIT2 database. 
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The various macro-geographical regions and sub-
regions were defined according to the specifications 
of the United Nations (http://en.wikipedia.org/wiki/
ISO_3166-1_alpha-3).
Data analysis
Clinical-demographic data was entered into the com-
puter using Epidata 3.1 software and then exported to 
SPSS version 21 for analysis. The spoligotyping data were 
digitized and analyzed with the BioNumerics software, 
version 5.0 (Applied Maths, Kortrijk, Belgium).
Statistical association between the dominant strain 
types and HIV sero-status were analyzed in a 2 × 2 con-
tingency table using Fisher’s exact test. A p value of <0.05 
was considered statistically significant. The independent 
T test was used to determine whether there was a statisti-




All of the 121 isolates were confirmed to be M. tubercu-
losis complex based on 16S-rRNA as well as the presence 
of the insertion sequence IS6110 that is highly conserved 
in all members of M. tuberculosis complex.
Spoligotypes
All of the 121 isolates had spoligotypes characteristic 
of M. tuberculosis. The spoligotype octal code outcome 
results were compared to the SIT and lineages/subline-
ages described in the SITVIT2 database. Spoligotyping 
revealed 52 distinct spoligotype patterns, of which 32 
patterns matched a pre-existing SIT in the SITVIT2 data-
base, whereas 4 SITs were newly created either within 
the present study or after a match with an orphan in the 
database (Table  1). Sixteen patterns were true orphans 
(Additional file 1: Table S1).
The T2 sublineage was predominant comprising 55 
(46 %) isolates, of which 46 were T2-Uganda, character-
ized by the absence of spacers 33–36 and spacer 40 and 
43 [24], while 2 isolates had the controversial signature 
T2/LAM3. The T2 sublineage was followed in frequency 
by the T1 sublineage with 19 (16 %) isolates. The Central 
Asian Strain (CAS) family comprised 16 (18 %) isolates, 
of which CAS1-Dehli was the most common with 10 iso-
lates followed by CAS1-Kili with 5 isolates. Other sublin-
eages were EAI5 with 3 isolates, Beijing 3, LAM11-ZWE 
3, MANU3 3 and LAM1 2. Seven spoligotypes could not 
be assigned to any sublineage.
The two predominant spoligotypes in our sample were 
SIT420 (T2-Uganda) with 13 (10.7  %) and SIT53 (T1) 
with 11 (19.8  %) isolates. Other significant spoligotypes 
identified in the sample were SIT128 (T2-Uganda) with 9 
(7.4 %) and SIT135 (T2-Uganda) with 10 (8.3 %) isolates 
(Table  1). Sixteen isolates had no assigned SIT accord-
ing to the SITVIT2 database and were true orphans 
(Additional file  1: Table S1). None of the predominant 
spoligotypes SIT420, SIT53 and SIT135 was signifi-
cantly associated with HIV infection. No association was 
found between the major spoligotypes and HIV infection 
(Additional file 2: Table S2).
Of the 12 SIT420 patients tested for HIV, 8/74 (10.8 %) 
were HIV negative whereas 4/38 (10.5 %) were HIV posi-
tive (p = 1.00). One patient did not consent to HIV test-
ing. Of ten SIT135 patients tested for HIV, 6/74 (8.1 %) 
were HIV negative while 4/38 (10.5  %) were HIV posi-
tive (p = 0.732). Ten SIT53 patients tested for HIV, 9/74 
(12.2  %) were HIV negative and 1/38 (2.6  %) were HIV 
positive (p = 0.16). One SIT53 patient did not consent to 
HIV testing.
No correlation between a particular spoligotype and 
gender or age was found (Additional file 3: Table S3).
RD analysis
RD9 analysis confirmed that all isolates were M. tuber-
culosis, while RD4 and RD14 analysis ruled out M. bovis. 
RD105 analysis identified three Beijing isolates. RD724 
analysis revealed 55 (46  %) isolates to be Uganda geno-
types, that is all the 55 isolates with a T2 spoligotype sig-
nature, lacking spacers 33–36 and spacer 40 and/or 43.
Two of the isolates, designated SIT125, which were 
deleted for RD724, were initially assigned to the LAM 
lineage according to the SITVITWEB database, although 
the spoligotype signature was a typical T2. Their designa-
tion in the SITVIT2 database has now been changed to 
T2/LAM3.
Phylogenetic analysis
Phylogenetic analysis showed the evolutionary relation-
ships between the spoligotypes of the 121 isolates (Fig. 1). 
One may notice in Fig. 1b, a long descendant branch of 
spoligotypes belonging to T2-Uganda sublineage con-
taining specifically SITs 135, 128 and 420, which supports 
an ongoing evolution of this sublineage in Uganda.
Worldwide distribution
We also attempted to describe the worldwide distribution 
of predominant SITs encountered in this study. As shown 
in Table  2, we observed that the isolates of the Uganda 
genotype were less frequently observed in countries out-
side Uganda (0–9 countries) than isolates of other sublin-
eages (6–13 countries).
Discussion
In this study of the genotypic diversity of M. tuberculosis 
strains causing EPTB in Uganda, EPTB was found to be 
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caused exclusively by M. tuberculosis. The Uganda geno-
type was the predominant genotype comprising 46 % of 
the isolates.
The Uganda genotype is defined by the RD724 deletion 
in combination with the lack of spacers 33–36 and spacer 
40 and/or 43 by spoligotyping [20, 21]. Interestingly all 
Table 1 Description of 36 SITs and corresponding spoligotyping defined lineages/sublineages starting from a total of 121 
M. tuberculosis strains isolated in Kampala, Uganda
SITa Spoligotype description No (%) in study







1  3 (2.48) 0.03 Beijing Clustered
4  3 (2.48) 0.78 Unknown Clustered
21  5 (4.13) 1.04 CAS1-Kili Clustered
25  1 (0.83) 0.15 CAS1-Delhi Unique
26  3 (2.48) 0.17 CAS1-Delhi Clustered
52  4 (3.31) 0.42 T2 Clustered
53  11 (9.09) 0.17 T1 Clustered
54  1 (0.83) 0.36 Manu2 Unique
59  3 (2.48) 0.61 LAM11-ZWE Clustered
78  2 (1.65) 2.82 T Clustered
125  2 (1.65) 1.80
T2/LAM3 (controversial 
signature) Clustered
126  3 (2.48) 1.97 EAI5 Clustered
128  9 (7.44) 20.45 T2-Uganda Clustered
135  10 (8.26) 22.22 T2-Uganda Clustered
149  1 (0.83) 0.20 T3-ETH Unique
182  1 (0.83) 16.67 H1 Unique
205  1 (0.83) 1.79 T1 Unique
226  1 (0.83) 11.11 Manu2 Unique
288  1 (0.83) 0.63 CAS2 Unique
356  5 (4.13) 26.32 CAS1-Delhi Clustered
358  1 (0.83) 3.45 T1 Unique
420  13 (10.74) 34.21 T2-Uganda Clustered
522  2 (1.65) 11.11 T1 Clustered
523  1 (0.83) 1.67 Manu_ancestor Unique
590  4 (3.31) 44.44 T2-Uganda Clustered
1166  1 (0.83) 2.13 T1 Unique
1339  1 (0.83) 33.33 T Unique
1570  1 (0.83) 20.0 Unknown Unique
2188  1 (0.83) 20.0 T2 Unique
2867  2 (1.65) 33.33 T2 Clustered
3502  1 (0.83) 33.33 Unknown Unique
4008  1 (0.83) 33.33 Manu3 Unique
4059a  2 (1.65) 100 Manu3 Clustered
4060a  1 (0.83) 50.0 T1 Unique
4061a  2 (1.65) 100 T2-Uganda Clustered
4062a  1 (0.83) 50.0 T2-Uganda Unique
a Newly created SITs are marked by lowercase alphabet a. Country distribution for newly created SITs was as follows: SIT4059a, n = 2 this study; SIT4060a, n = 1 this 
study, n = 1 PRT; SIT4061a n = 2 this study; SIT4062a n = 1 this study, n = 1 ZMB
b Lineage designations according to SITVIT2; “unknown” designates patterns with signatures that do not belong to any of the major lineages described in the 
database
c Clustered strains correspond to a similar spoligotype pattern shared by 2 or more strains “within this study”; as opposed to unique strains harboring a spoligotype 
pattern that does not match with another strain from this study. Unique strains matching a preexisting pattern in the SITVIT2 database are classified as SITs, whereas 
in case of no match, they are designated as “orphan”
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isolates of the T2 sublineage were of the Uganda geno-
type, indicating that the RD724 deletion may be a marker 
of a majority of the T2 sublineage, a matter that needs to 
be further explored.
In a phylogenetic analysis SIT420 (T-2 Uganda), the 
most common spoligotype in this study was at the tip of 
a long descendant branch of spoligotypes belonging to 
the T2-Uganda sublineage, and this supports the ongo-
ing evolution of this sublineage in Uganda. The fact that 
SIT420 is only reported in three other countries (USA, 
Tanzania and Belgium) in the SITVIT2 database supports 
the theory that Uganda is at the center of this evolution.
Following SIT420, SIT53 was the most prevalent spo-
ligotype. SIT53 has been reported in several countries 
in sub-Saharan Africa. In a study performed in Cote 
d´Ivoire, SIT53 was the most predominant spoligotype in 
PTB retreated patients [25]. In a study from South Africa, 
SIT53 was the most frequent spoligotype and was associ-
ated with mixed infections [26]. However, in three previ-
ous studies in Uganda SIT53 was either rare [27, 28] or 
absent [11].
Two studies involved PTB patients from Southwestern 
Uganda [28] and peri-urban Kampala [11], respectively, 
while in one study the patients had either PTB or EPTB 
[27].
Although the Uganda genotype is the predominant 
genotype, it appears to be a less frequent aetiological 
agent in EPTB than in PTB. In a study of M. tubercu-
losis complex isolates from PTB done in the same set-
ting [11], the Uganda genotype accounted for 70  % of 
Fig. 1 Phylogenetical analysis illustrating evolutionary relationships between M. tuberculosis spoligotypes in Kampala, Uganda (n = 121 isolates). 
a Minimum Spanning Tree (MST) constructed on all isolates. Separations between the nodes represent the number of strains shared by a given 
spoligotype pattern. The links between nodes indicate the distance (darker and bolder lines mean a unique change whereas finer gray lines, continued, 
dotted or dashed, indicate more changes). b Spoligoforest tree drawn as a hierarchical layout; and c spoligoforest tree drawn using the Fruchter-
man–Reingold algorithm. Both spoligoforests were drawn using the spolTools software (http://www.emi.unsw.edu.au/spoltools/). Loss of spacers 
is represented by directed edges between nodes, and the arrowheads point to descendant spoligotypes. The heuristic used selects a single inbound 
edge with a maximum weight using a Zipf model. Solid black lines link patterns that are very similar, i.e. loss of one spacer only (maximum weight 
being 1.0), while dashed lines represent links of weight comprised between 0.5 and 1, and dotted lines a weight less than 0.5
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isolates compared to 46  % seen in this current study. A 
more recent longitudinal study of sputum isolates in cen-
tral Uganda also showed predominance of the Uganda 
genotype of M. tuberculosis at 63  % over a period from 
1992 to 2009 [29], and in a study of sputum isolates done 
in Southwestern Uganda, 59.2  % of the isolates were of 
Uganda genotype [19]. In another study done on PTB 
and EPTB subjects in a rural central Uganda district hos-
pital, 23 different spoligotypes were detected comprising 
predominantly T2 with subtypes Uganda I and Uganda II 
[27], which are both characterized by lack of hybridiza-
tion to spacer 40, while in addition, strains of genotype 
Uganda I also lack spacer 43 [19].
The combination of spoligotyping and deletion analy-
sis revealed one incongruence: two isolates, designated 
SIT125 (signature being loss of spacers 1–24, 33–36 
and 40) which were deleted for RD724, were originally 
assigned to the LAM lineage according to the SITVIT2 
database. By spoligotyping, the Euro-American line-
age consists of the sublineages T, Haarlem, LAM, S and 
X. The spoligotype patterns of isolates from different 
lineages may converge by deletion of single or contiguous 
spacers in the direct repeat (DR) locus [20]. Although the 
phenomenon of homoplasy in the DR locus leading to 
convergent evolution to identical spoligotypes is consid-
ered a rare event [21], it argues against the use of spoligo-
typing for establishing phylogenetic relationships within 
the Euro-American lineage [30].
Indeed SIT125 with its characteristically ‘abridged’ 
profile could be linked either to T2 or LAM3 as well as an 
underlying S-lineage signature. It was initially classified 
as T2 in the SpolDB4 database and later reclassified as 
LAM3 in SITVITWEB, both being feasible based strictly 
on spoligotyping signatures. Although its definitive clas-
sification remains controversial, parallel data show its 
high phylogeographical specificity for Bulgaria [31]. In 
that paper, a possible relatedness with the SIT34 spo-
ligotype (prototype of the S family) was suggested. Fur-
thermore, an absence of LAM-specific IS6110 insertion, 
which suggested that SIT125 (at least those from Bul-
garia) were most probably not LAM. However, a study 
from Brazil on RDRio [32] showed that although 4/5 
Table 2 Description of clusters observed in our study and their worldwide distribution in the SITVIT2 database
SIT (Lineage) Octal number
spoligotype description
No (%) 
in study Distribution in regions with ≥3% of a given SIT
a Distribution in countries with ≥3% of a given SITb
SIT1 (Beijing) 000000000003771

3 (2.48) ASIA-E 32.34, AMER-N 19.01, ASIA-SE 10.11, AFRI-S 7.85, ASIA-N 6.59, ASIA-S 5.63, EURO-N 3.46, AMER-S 3.44




3 (2.48) EURO-S 15.93, AMER-S 14.62, AMER-N 12.01, EURO-W 10.44, ASIA-W 10.18, AFRI-E 8.88, AFRI-S 7.83, EURO-N 6.01, EURO-E 5.48, CARI 3.66
USA 9.4, BRA 9.14, ITA 8.62, ZAF 7.83, TUR 7.57, BGR 5.22, ETH 4.18, 
FXX 3.92, ALB 3.92
SIT21 (CAS1-Kili) 703377400001771

5 (4.13) AFRI-E 66.32, EURO-N 9.98, EURO-W 6.24, ASIA-W 5.2, AMER-N 5.2, AFRI-S 4.78








EURO-W 18.8, ASIA-E 14.85, EURO-N 13.29, AMER-N 11.53, AFRI-E 5.19, 
EURO-S 5.09, ASIA-W 5.09, AFRI-M 5.09, EURO-E 4.15, AMER-C 3.32, 
AMER-S 3.22
CHN 11.53, USA 11.11, SWE 9.35, FXX 8.62, BEL 4.67, CMR 4.15, ITA 




AMER-S 14.95, EURO-W 14.8, AMER-N 12.75, EURO-S 8.9, EURO-N 7.07, 
ASIA-W 6.91, AFRI-E 4.79, AFRI-S 4.7, ASIA-E 4.03, AFRI-N 3.33, EURO-E 
3.09, CARI 3.06, AMER-C 3.06




3 (2.48) AFRI-E 58.61, AFRI-S 15.16, EURO-W 14.55, AMER-N 3.28 ZMB 21.72, ZWE 15.78, ZAF 15.16, BEL 13.32, TZA 11.07, USA 3.28, MWI 3.28
SIT78 (T) 777777777760711

2 (1.65) AFRI-E 22.54, ASIA-W 14.09, ASIA-S 11.27, EURO-N 8.45, AMER-S 8.45, EURO-W 7.04, AMER-N 7.04, EURO-S 5.63, EURO-E 4.22 MDG 18.31, IND 11.27, TUR 8.45, USA 7.04, SAU 4.22, GBR 4.22
SIT125/T2/LAM3 (Controversial Signature) 000000007760731

2 (1.65) EURO-E 66.67, EURO-W 9.91, AMER-S 6.31, AFRI-S 3.6, EURO-S 2.7, AMER-N 2.7, AFRI-E 2.7, ASIA-S 1.8, ASIA-E 1.8, ASIA-W 0.9, AFRI 0.9, BGR 66.67, NLD 5.41, ZAF 3.6, BRA 3.6
SIT126 (EAI5) 477777777413771

3 (2.48) ASIA-S 36.84, AFRI-E 17.11, ASIA-W 16.45, EURO-N 13.16, EURO-W 5.26, ASIA-SE 3.95, AMER-N 3.95




9 (7.44) AFRI-E 40.91, EURO-W 31.82, AFRI-S 20.45 ZAF 20.45, UGA 20.45, TZA 13.64, FXX 11.36, DEU 9.09, ZMB 6.82, NLD 6.82, BEL 4.55
SIT135 (T2-Uganda) 777777777760730

10 (8.26) AFRI-E 35.56, EURO-W 26.67, AMER-N 13.33, AFRI-S 13.33, ASIA-W 4.44 UGA 24.44, ZAF 13.33, USA 13.33, TZA 8.89, DEU 8.89, NLD 6.67, AUT 6.67, SAU 4.44, FXX 4.44
SIT356 (CAS1-Delhi) 703777600001771

5 (4.13) AFRI-S 26.32, AFRI-E 26.32, EURO-N 15.79, ASIA-S 10.53, AFRI-N 10.53, ASIA-W 5.26, AMER-N 5.26




13 (10.74) AFRI-E 60.53, AMER-N 21.05, EURO-W 15.79 UGA 36.84, USA 21.05, TZA 21.05, BEL 13.16
SIT522 (T1) 777777777760770

2 (1.65) AMER-N 22.22, AFRI-E 22.22, EURO-W 16.67, AFRI-W 11.11, EURO-S 5.56, CARI 5.56, ASIA-W 5.56, ASIA-SE 5.56, AMER-C 5.56
USA 22.22, UGA 11.11, GNB 11.11, YEM 5.56, TZA 5.56, NLD 5.56, MEX
5.56, KEN 5.56, ITA 5.56, IDN 5.56, HTI 5.56, FXX 5.56, AUT 5.56
SIT590 (T2-Uganda) 777777403760730

4 (3.31) EURO-W 44.44, AFRI-E 44.44, AMER-N 11.11 UGA 44.44, BEL 22.22, USA 11.11, FXX 11.11, DEU 11.11
SIT2867 (T2) 777777775760731

2 (1.65) AFRI-E 33.33, ASIA-W 16.67, ASIA-S 16.67, AFRI-S 16.67, AFRI-N 16.67 UGA 33.33, ZAF 16.67, TUN 16.67, SAU 16.67, PAK 16.67
SIT4059 (Manu3) 777357776770731

2 (1.65) AFRI-E 100.0 UGA 100.0
SIT4061 (T2-Uganda) 777775777760730

2 (1.65) AFRI-E 100.0 UGA 100.0
a Worldwide distribution is reported for regions with more than 3 % of a given SITs as compared to their total number in the SITVIT2 database. The definition of 
macro-geographical regions and sub-regions (http://unstats.un.org/unsd/methods/m49/m49regin.htm) is according to the United Nations; Regions: AFRI (Africa), 
AMER (Americas), ASIA (Asia), EURO (Europe), and OCE (Oceania), subdivided in: E (Eastern), M (Middle), C (Central), N (Northern), S (Southern), SE (South-Eastern), 
and W (Western). Furthermore, CARIB (Caribbean) belongs to Americas, while Oceania is subdivided in four sub-regions, AUST (Australasia), MEL (Melanesia), MIC 
(Micronesia), and POLY (Polynesia). Note that in our classification scheme, Russia has been attributed a new sub-region by itself (Northern Asia) instead of including 
it among rest of the Eastern Europe. It reflects its geographical localization as well as due to the similarity of specific TB genotypes circulating in Russia (a majority of 
Beijing genotypes) with those prevalent in Central, Eastern and South-Eastern Asia
b The three letter country codes are according to http://en.wikipedia.org/wiki/ISO_3166-1_alpha-3; countrywide distribution is only shown for SITs with ≥3 % of a 
given SITs as compared to their total number in the SITVIT2 database. Note that FXX code designates Metropolitan France
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SIT125 strains were not LAM, 1/5 strain was LAM/RD-
Rio. The SIT125 designation in the SITVIT2 database has 
now been changed to the controversial signature of T2/
LAM3, while the exact phylogenetic position of SIT125 is 
debated and possible homoplasy in spoligotyping defined 
lineages is considered. For this reason, in this current 
study we have chosen to assign the two SIT125 isolates to 
the T2 lineage.
A previous PTB study from Uganda [11] indicated 
SIT128, SIT135, SIT52, SIT590 and SIT125 as the major 
SITs. SIT420, the predominant spoligotype in our study, 
was not identified in an urban area of Kampala [11] 
and was found only in low proportion in Southwestern 
Uganda [19] in patients with PTB. However, in a study 
from central Uganda [27] of both PTB and EPTB (lymph 
node isolates) SIT420 was the most prevalent with a clus-
ter rate of 14.8 %, and mostly recovered from rural resi-
dents. In a study of sputum isolates from the neighboring 
country of Rwanda, SIT420 was the third most common 
spoligotype [33].
SIT52 constituted 3.3  % of the isolates compared to 
7.6  % (26/334) seen in PTB in central Uganda [11] and 
4.8 % (6/125) in Southwestern Uganda [19]. In Ethiopia, 
SIT54, SIT53 and SIT149 were the most dominant spoli-
gotypes in EPTB while T1 was the most dominant sublin-
eage [34]. Previous evidence from Italy however indicates 
that CAS lineages are associated with EPTB [35]. A more 
recent study of EPTB conducted in India also showed 
spoligotypes belonging to the CAS family (57.27 %) were 
predominant [36].
There is evidence of genotypic linkage of strains iso-
lated from patients from a distinctive geographical region 
regardless of whether the patients acquired the infection 
from their current locality or had reactivated disease 
from their native country, this suggests that M. tubercu-
losis lineages may be adapted to particular genetic, cul-
tural or environmental characteristics of the host [37]. 
Most of the genotypes in this study were similar to those 
previously found in PTB isolates in the same area [11], 
supporting the concept that EPTB and PTB are caused 
by the same type of strains and that mainly host factors 
determine whether PTB will transient through the lung 
to establish as chronic lymphatic disease [38]. The quan-
titative differences in spoligotype patterns could partly be 
due to the fact that Mulago Hospital is a national referral 
hospital, which has the largest TB diagnostic and treat-
ment facilities in the country.
The lower prevalence of the Uganda genotype in this 
current study of EPTB isolates, compared to studies of 
PTB isolates in the same location indicates that other 
genotypes may be more prone to cause EPTB. The fact 
that the predominant SIT420 and SIT53 in this study 
was not seen in the PTB isolates previously studied [11] 
is another intriguing difference between EPTB and PTB 
in this setting. The observations merit future prospec-
tive studies in which isolates from patients from the same 
rural and urban region with EPTB and PTB are com-
pared head to head at the same time.
Evidence from previous studies indicate that patho-
gen characteristics also determine whether patients 
present with PTB or EPTB [39, 40]. Thus, strains of the 
Euro-American lineage (to which the Uganda genotype 
belongs) may be more likely to cause pulmonary disease 
and less capable of extrapulmonary dissemination [41].
Studies in the United States indicate that Indo-Oce-
anic and East Indian lineages of MTB were associated 
with a higher frequency of exclusively EPTB [42]. It is 
noteworthy that none of the predominant spoligotypes 
or sublineages was significantly associated with HIV 
infection.
In Uganda M. bovis control efforts are unsatisfactory 
which has increased the incidence of this infection in the 
population, and therefore the complete absence of M. 
bovis in the current study is worth noting. This absence 
of M. bovis was also seen in studies from Ethiopia [43]. 
Even in pastoralists [43] no M. bovis was isolated from 
lymph node fine needle biopsies despite close contact 
between humans and livestock, including consumption 
of raw milk and meat. But in another study from South-
ern Ethiopia, six of 35 (17.1 %) PCR positive patients with 
tuberculous lymphadenitis were found to have M. bovis 
[44]. Findings from a study in Tanzania of cervical adeni-
tis patients confirmed that 10.8 % of the cases were due 
to M. bovis [45]. Thus, there is increasing evidence that 
M. bovis is at least a minor cause of human lymphadenitis 
in African countries.
Conclusion
In conclusion, EPTB was caused exclusively by M. tuber-
culosis and the Uganda genotype was the predominant 
genotype, although at a lower frequency than in studies 
of PTB in the same location. The spoligotypes were in 
most cases similar to those causing PTB with the excep-
tion of SIT420 which predominated in EPTB but are 
mainly lacking in other studies of PTB. Exploring the 
diversity of M. tuberculosis is essential in appreciating the 
clinical manifestations and pathogenesis of the disease, as 
well as the development of new diagnostic strategies.
Mtb lineages are geographically restricted and may 
adapt to local human populations. Effective vaccine can-
didates may in future have to be evaluated against pre-
vailing Mtb genotypes and host genetic backgrounds.
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